Great Valley Advisor Group Inc. Grows Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Great Valley Advisor Group Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 19.9% in the third quarter, Holdings Channel reports. The institutional investor owned 11,824 shares of the biopharmaceutical company’s stock after acquiring an additional 1,959 shares during the quarter. Great Valley Advisor Group Inc.’s holdings in Gilead Sciences were worth $886,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Arrowstreet Capital Limited Partnership grew its position in shares of Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after purchasing an additional 13,764,169 shares in the last quarter. Norges Bank purchased a new position in shares of Gilead Sciences during the 4th quarter valued at $1,115,186,000. Moneta Group Investment Advisors LLC grew its position in shares of Gilead Sciences by 96,759.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 10,111,194 shares of the biopharmaceutical company’s stock valued at $868,046,000 after purchasing an additional 10,100,755 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Gilead Sciences by 70.6% during the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock valued at $921,006,000 after purchasing an additional 6,410,047 shares in the last quarter. Finally, Capital World Investors grew its position in shares of Gilead Sciences by 5.8% during the 2nd quarter. Capital World Investors now owns 80,929,316 shares of the biopharmaceutical company’s stock valued at $6,237,075,000 after purchasing an additional 4,429,076 shares in the last quarter. 82.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on GILD shares. Leerink Partnrs restated a “market perform” rating on shares of Gilead Sciences in a research report on Wednesday, October 11th. StockNews.com assumed coverage on shares of Gilead Sciences in a report on Thursday, October 5th. They set a “strong-buy” rating for the company. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Gilead Sciences in a report on Thursday, November 9th. They set a “hold” rating and a $75.00 price objective for the company. Royal Bank of Canada dropped their price objective on shares of Gilead Sciences from $78.00 to $77.00 and set a “sector perform” rating for the company in a report on Tuesday, November 14th. Finally, UBS Group dropped their price objective on shares of Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating for the company in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $87.20.

Check Out Our Latest Research Report on GILD

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $78.62 on Wednesday. The company has a market cap of $97.96 billion, a price-to-earnings ratio of 16.87, a price-to-earnings-growth ratio of 0.95 and a beta of 0.24. The company has a 50-day moving average price of $80.66 and a 200-day moving average price of $78.33. The company has a current ratio of 1.34, a quick ratio of 1.20 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 12 month low of $72.87 and a 12 month high of $87.86.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $2.29 EPS for the quarter, beating the consensus estimate of $1.91 by $0.38. The firm had revenue of $7.05 billion during the quarter, compared to the consensus estimate of $6.81 billion. Gilead Sciences had a net margin of 21.45% and a return on equity of 39.30%. The company’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.90 earnings per share. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 6.77 EPS for the current year.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total transaction of $428,900.00. Following the transaction, the chief financial officer now owns 101,534 shares in the company, valued at $8,709,586.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Johanna Mercier sold 8,242 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the transaction, the insider now owns 82,729 shares in the company, valued at $7,050,992.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 5,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total transaction of $428,900.00. Following the transaction, the chief financial officer now owns 101,534 shares in the company, valued at approximately $8,709,586.52. The disclosure for this sale can be found here. Insiders own 0.21% of the company’s stock.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.